Berberine
(Synonyms: 黄连素; Natural Yellow 18) 目录号 : GN10221
小檗碱（Natural Yellow 18）是一种从中草药黄连中分离出来的生物碱，作为一种抗生素。
Cas No.:2086-83-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Berberine (Natural Yellow 18) is an alkaloid isolated from the Chinese herbal medicine Huanglian, as an antibiotic. Berberine (Natural Yellow 18) induces reactive oxygen species (ROS) generation and inhibits DNA topoisomerase. Berberine (Natural Yellow 18) has antineoplastic properties[1].
Berberine (1.25-160 μM; 72 hours) has potential inhibitory effects on the proliferation of four colorectal carcinoma cell lines LoVo, HCT116, SW480, and HT-29[1]. Berberine (1.25-160 μM; 24-72 hours) induces a time- and dose-dependent inhibition of LoVo cell growth[1]. LoVo cells are exposure to Berberine (10-80 μM) for 24 h. Cell cycle analysis of 40 μM Berberine-treated LoVo cells by flow cytometry shows accumulation of cells in the G2/M phase[1].Berberine (10-80 μM) suppresses cyclin B1, cdc2 and cdc25c protein expression after 24 h, especially at the dose of 80.0 μM[1].
Berberine (10, 30, or 50 mg/kg/day; gastrointestinal gavage; for 10 consecutive days) inhibits the growth of human colorectal adenocarcinoma in vivo. Berberine at doses of 30 and 50 mg/kg/day taken by gastrointestinal gavage shows inhibitory rates of 33.1% and 45.3% on the human colorectal adenocarcinoma xenograft growth in nude mice[1].
黄连素（天然黄18）是从中国草药黄连中分离出的一种生物碱，具有抗生素的作用。黄连素能够诱导产生活性氧自由基（ROS），并抑制DNA拓扑异构酶。黄连素具有抗肿瘤的特性[1]。
黄连素（1.25-160 μM；72小时）对四种结肠癌细胞系LoVo、HCT116、SW480和HT-29的增殖具有潜在的抑制作用[1]。黄连素（1.25-160 μM；24-72小时）呈现出对LoVo细胞生长的时间和剂量依赖性抑制作用[1]。将LoVo细胞暴露于10-80 μM浓度的黄连素中处理24小时后，通过流式细胞术分析显示，40 μM浓度的黄连素可导致细胞在G2/M期的积累[1]。黄连素（10-80 μM）可在24小时后抑制cyclin B1、cdc2和cdc25c蛋白表达，尤其在80.0 μM的浓度下表现更为显著[1]。
黄连素（10、30或50 mg/kg/天；经胃灌注；连续10天）能够抑制人类结肠腺癌在体内的生长。黄连素以30和50 mg/kg/天的剂量经胃灌注可分别对裸鼠人类结肠腺癌异种移植物的生长呈现出33.1%和45.3%的抑制率[1]
References:
[1]. Cai Y, et al. Berberine inhibits the growth of human colorectal adenocarcinoma in vitro and in vivo. J Nat Med. 2014 Jan;68(1):53-62.
| Cell experiment [1]: | |
|
Cell lines |
human hepatoma cell lines (HepG2 cells) |
|
Preparation method |
General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
|
Reacting condition |
0.5, 2.5, 5, 7.5, 10, 15 μg/ml, 24 h |
|
Applications |
Berberine as a new upregulator of liver LDLR (low-density lipoprotein receptor) expression. In HepG2 cells, the effect of berberine was also dose dependent. Northern blot showed a 50% increase in LDLR mRNA in cells treated with 2.5 μg/ml of berberine and a maximal increase of four fold of control was seen with a concentration of 15 μg/ml. The effect of BBR on LDLR was further confirmed in another human hepatoma cell line, Bel-7402. BBR at 2.5 μg/ml increased the LDLR mRNA in these cells by 2.3-fold. |
| Animal experiment [2]: | |
|
Animal models |
female golden hamsters |
|
Dosage form |
orally twice a day at 50 mg/kg/d or 100 mg/kg/d for 10 d. |
|
Application |
In hamsters, treatment of these hyperlipidemic animals with berberine by oral administration for 10 d resulted in dose-dependent decreases in both serum total cholesterol and LDL-c. After the 10-d treatment, berberine at a dose of 50 mg/kg/d reduced LDL-c by 26%, and at a dose of 100 mg/kg/d, reduced LDL-c by 42% as compared to the control animals on the same HFHC (high-fat and high-cholesterol) diet. The berberine effect was also time dependent. LDLR mRNA and protein levels were elevated in all berberine -treated hamsters in a dose-dependent manner. A 3.5-fold increase in mRNA and a 2.6-fold increase in protein in hamster livers treated with 100 mg/kg/d of berberine were detected. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Kong, W.,Wei, J.,Abidi, P., et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nature Medicine 10(12), 1344-1351 (2004). |
|
| Cas No. | 2086-83-1 | SDF | |
| 别名 | 黄连素; Natural Yellow 18 | ||
| 化学名 | 9,10-dimethoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-7-ium | ||
| Canonical SMILES | [H]C(C([H])([H])C1=C2[H])([H])[N+](C([H])=C(C(OC([H])([H])[H])=C3OC([H])([H])[H])C(C([H])=C3[H])=C4[H])=C4C1=C([H])C5=C2OC([H])([H])O5 | ||
| 分子式 | C20H18NO4 | 分子量 | 336.36 |
| 溶解度 | ≥ 14.95mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.973 mL | 14.865 mL | 29.7301 mL |
| 5 mM | 0.5946 mL | 2.973 mL | 5.946 mL |
| 10 mM | 0.2973 mL | 1.4865 mL | 2.973 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet